Immunoglobulin superfamily(IgSF)members account for a large proportion of cell adhesion molecules that perform important immunological functions,including recognizing a variety of counterpart molecules on the cell sur...Immunoglobulin superfamily(IgSF)members account for a large proportion of cell adhesion molecules that perform important immunological functions,including recognizing a variety of counterpart molecules on the cell surface or extracellular matrix.The findings that CD155/poliovirus receptor(PVR)and CD112/nectin-2 are the ligands for CD226/platelet and T-cell activation antigen 1(PTA1)/DNAX accessory molecular-1(DNAM-1),CD96/tactile and Washington University cell adhesion molecule(WUCAM)and that CD226 is physically and functionally associated with lymphocyte function-associated antigen-1(LFA-1)on natural killer(NK)and activated T cells have largely expanded our knowledge about the functions of CD226,CD96,WUCAM and LFA-1 and their respective ligands,CD155,CD112,intercellular adhesion molecule(ICAM)-1 and junctional adhesion molecule(JAM)-1.The interactions of these receptors and their ligands are involved in many key functions of immune cells including naive T cells,cytotoxic T cells,NK cells,NK T cells,monocytes,dendritic cells,mast cells and platelets/megakaryocytes.展开更多
目前,针对抑制性受体或配体、PD-1/PD-L1及CTLA-4的靶向免疫治疗已经取得了显著的临床成果,然而仍有许多患者未从免疫治疗中获益。因此,有必要寻找新的靶点及治疗方法,以提高免疫治疗的应答率。淋巴细胞上的T细胞免疫球蛋白及其ITIM结构...目前,针对抑制性受体或配体、PD-1/PD-L1及CTLA-4的靶向免疫治疗已经取得了显著的临床成果,然而仍有许多患者未从免疫治疗中获益。因此,有必要寻找新的靶点及治疗方法,以提高免疫治疗的应答率。淋巴细胞上的T细胞免疫球蛋白及其ITIM结构域(T-cell immunoreceptor with immunoglobulin and ITIM domains,TIGIT)、CD226和CD112R等均属于免疫球蛋白超家族受体,与不同配体结合后传递抑制或激活信号,他们复杂的相互作用形成的整合信号能够调节免疫细胞的功能。对靶向TIGIT、CD226和CD112R的免疫治疗研究进展进行综述,包括TIGIT、CD226、CD112R的生物学特性,抑制肿瘤或促进肿瘤的机制,靶向治疗的研究进展。展开更多
基金This work was supported by the National Natural Science Foundation of China(Nos.30801003,30972683 and 30901310).
文摘Immunoglobulin superfamily(IgSF)members account for a large proportion of cell adhesion molecules that perform important immunological functions,including recognizing a variety of counterpart molecules on the cell surface or extracellular matrix.The findings that CD155/poliovirus receptor(PVR)and CD112/nectin-2 are the ligands for CD226/platelet and T-cell activation antigen 1(PTA1)/DNAX accessory molecular-1(DNAM-1),CD96/tactile and Washington University cell adhesion molecule(WUCAM)and that CD226 is physically and functionally associated with lymphocyte function-associated antigen-1(LFA-1)on natural killer(NK)and activated T cells have largely expanded our knowledge about the functions of CD226,CD96,WUCAM and LFA-1 and their respective ligands,CD155,CD112,intercellular adhesion molecule(ICAM)-1 and junctional adhesion molecule(JAM)-1.The interactions of these receptors and their ligands are involved in many key functions of immune cells including naive T cells,cytotoxic T cells,NK cells,NK T cells,monocytes,dendritic cells,mast cells and platelets/megakaryocytes.
文摘目前,针对抑制性受体或配体、PD-1/PD-L1及CTLA-4的靶向免疫治疗已经取得了显著的临床成果,然而仍有许多患者未从免疫治疗中获益。因此,有必要寻找新的靶点及治疗方法,以提高免疫治疗的应答率。淋巴细胞上的T细胞免疫球蛋白及其ITIM结构域(T-cell immunoreceptor with immunoglobulin and ITIM domains,TIGIT)、CD226和CD112R等均属于免疫球蛋白超家族受体,与不同配体结合后传递抑制或激活信号,他们复杂的相互作用形成的整合信号能够调节免疫细胞的功能。对靶向TIGIT、CD226和CD112R的免疫治疗研究进展进行综述,包括TIGIT、CD226、CD112R的生物学特性,抑制肿瘤或促进肿瘤的机制,靶向治疗的研究进展。
